Clinical Trial Update: Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating FluBHPVE6E7 immunotherapy for HPV16-associated oropharyngeal squamous cell carcinoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• FluBHPVE6E7 Immunotherapy (FluBHPVE6E7)

Snippet

Sponsor: BlueSky Immunotherapies GmbH | Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC) | Phase 1 | Status: RECRUITING